- Home
- AREB vs QLGN Comparison
AREB vs QLGN Comparison
Compare AREB & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AREB
- QLGN
- Stock Information
- Founded
- AREB 2014
- QLGN 1996
- Country
- AREB United States
- QLGN United States
- Employees
- AREB N/A
- QLGN N/A
- Industry
- AREB Plastic Products
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- AREB Industrials
- QLGN Health Care
- Exchange
- AREB Nasdaq
- QLGN Nasdaq
- Market Cap
- AREB 2.8M
- QLGN 2.4M
- IPO Year
- AREB N/A
- QLGN N/A
- Fundamental
- Price
- AREB $0.87
- QLGN $3.55
- Analyst Decision
- AREB
- QLGN
- Analyst Count
- AREB 0
- QLGN 0
- Target Price
- AREB N/A
- QLGN N/A
- AVG Volume (30 Days)
- AREB 139.9K
- QLGN 110.9K
- Earning Date
- AREB 02-07-2025
- QLGN 04-07-2025
- Dividend Yield
- AREB N/A
- QLGN N/A
- EPS Growth
- AREB N/A
- QLGN N/A
- EPS
- AREB N/A
- QLGN N/A
- Revenue
- AREB $14,447,104.00
- QLGN N/A
- Revenue This Year
- AREB $45.19
- QLGN N/A
- Revenue Next Year
- AREB N/A
- QLGN N/A
- P/E Ratio
- AREB N/A
- QLGN N/A
- Revenue Growth
- AREB N/A
- QLGN N/A
- 52 Week Low
- AREB $0.85
- QLGN $2.96
- 52 Week High
- AREB $9.27
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- AREB 25.16
- QLGN 47.06
- Support Level
- AREB $0.85
- QLGN $3.16
- Resistance Level
- AREB $1.14
- QLGN $3.75
- Average True Range (ATR)
- AREB 0.11
- QLGN 0.21
- MACD
- AREB -0.01
- QLGN 0.06
- Stochastic Oscillator
- AREB 4.08
- QLGN 67.25
About AREB American Rebel Holdings Inc.
American Rebel Holdings Inc develops self-defense, safe storage, and patriotic products. It designs, manufactures, and markets concealed carry products. It offers products ranging in Backpacks, vault doors, and Others.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.